SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Dimension Therapeutics, Inc (DMTX)

Add DMTX Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/4/2016 8:08:22 AM - Followers: 1 - Board type: Free - Posts Today: 0

Portfolio of gene therapy treatment

Dimension’s programs address significant unmet medical needs for patients living with hemophilia and rare diseases associated with the liver. The Company’s lead program in hemophilia B is currently in phase I/II clinical testing. The company is also advancing programs through preclinical testing to address hemophilia A in collaboration with Bayer HealthCare and for patients living with ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa). Additional programs addressing citrullinemia type 1, phenylketonuria, and Wilson disease in candidate selection continue to broaden and expand our liver-directed rare disease platform.

Dimension’s therapies use the biology of the parvovirus (adeno-associated virus (AAV)) to carry the missing gene in the body to the target cell with the aim of correcting the defect and providing meaningful clinical benefit to the lives of patients. This platform has demonstrated early validation and compelling preclinical in vivo proof of concept across multiple disease states in leading academic research centers.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
DMTX News: Dimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and... 10/18/2016 08:00:00 AM
DMTX News: Dimension Therapeutics Announces Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Congress 10/11/2016 08:00:00 AM
DMTX News: Dimension Therapeutics Announces Orphan Drug Designation of DTX401 for the Treatment of Glycogen Storage Disease Type Ia (GSD... 10/04/2016 08:00:00 AM
DMTX News: Confidential Treatment Order (ct Order) 09/06/2016 05:24:15 PM
DMTX News: Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences 08/24/2016 08:00:00 AM
#3   there's the news... HeavyDd 10/04/16 08:08:22 AM
#2   link to FDA website... HeavyDd 09/30/16 07:44:16 PM
#1   DMTX drug granted orphan drug status HeavyDd 09/30/16 07:15:28 PM